has the following hallmarks:
It is transversal across specialties, encompassing several teams throughout various fields and disciplines (research teams, clinical departments, technological platforms)
It is comprehensive in terms of spanning all phases of clinical trials developing innovative programs (such as MOSCATO-02, liquid biopsies, immunosenescence prospective cohort) in oncology as well as re-evaluating and improving current concepts (vaccinology, tumor microenvironment, precision medicine). It concerns various cancers (melanoma, breast cancers, NSCLC, H&N, RCC, leukemia…) and others through specific Phase I-II/III trials
It requires cutting-edge technologies: efforts will be undertaken toward strengthening bioinformatics capabilities (network, storage, cluster, databases, bioinformatician engineers etc) and creating a cell free circulating DNA platform. Such investments are crucial for fulfilling our scientific programs
It supports emergence of innovative translational research projects through call for proposals within Gustave Roussy, for clinician-biologist associations
It promotes knowledge dissemination, with the organization of an annual conference bridging together immunotherapy and radiotherapy (ImmunoRad), in collaboration with US cancer center from Weill Cornell Medicine (New-York)
It pushes forward health democracy through the inclusion a patient in our steering committee, and a dedicated social sciences program about equality of access to biomedical innovation in oncology
DNA Damage Response (DDR)
|Patricia Kannouche||Sophie Postel-Vinay|
To ensure the integrity of the genome and hence the fitness and viability of cells, DNA lesions that are formed as a result of various toxic assaults are normally repaired by an elaborate network of DNA damage response (DDR) pathways.
To ensure the integrity of the genome and hence the fitness and viability of cells, DNA lesions that are formed as a result of various toxic assaults are normally repaired by an elaborate network of DNA damage response (DDR) pathways. Interestingly, DNA is also the main target of most chemotherapeutic agents and ionizing radiations, two key components of anti-cancer therapy. GRCC has contributed to elucidating DNA repair pathways and their abnormalities for over 30 years. SOCRATE 2.0 will focus on better understanding the crosstalk between DNA damage, DNA damage response pathways and inflammation, in order to design new diagnostic, prognostic, and therapeutic strategies for chemotherapy, radiotherapy, DNA damage/DDR- associated targeted therapies.
|Laurence Zitvogel||Aurélien Marabelle|
The discovery of cancer immune checkpoints and the successes of immune- and tumor -targeted antibodies have changed the landscape of the clinical management of various malignancies.
The discovery of cancer immune checkpoints and the successes of immune- and tumor -targeted antibodies have changed the landscape of the clinical management of various malignancies. The hallmarks of oncogenesis are now encompassing inflammation and immunosuppression. Teams from SOCRATE 2.0 have a long lasting commitment to immunology with key contributions to decipher new concepts (immunogenic cell death, resistance to immune modulation, tumor antigens, immunosurveillance, monoclonal antibodies therapy). Future challenges rely on understanding mechanisms to circumvent the primary and secondary resistances to immune attacks in order to exploit and foster the numerous clinically relevant next generation trials combining conventional-, tumor targeted- and immune-targeted -therapies.
Cancer Molecular Dynamics
|Fabrice André||Olivier Bernard|
Molecular medicine also called precision or personalized medicine is a scientific approach based on molecular analyses that drive methods for early diagnosis, and guidance for targeted therapies.
Molecular medicine also called precision or personalized medicine is a scientific approach based on molecular analyses that drive methods for early diagnosis, and guidance for targeted therapies. The SOCRATE 2.0 program aims at identifying targets and validating the molecular-driven therapeutic strategies. The long-term vision is to propose an extensive molecular analysis to each patient with difficult-to-treat cancer in order to propose a personalized therapy. These new operational rules in cancer medicine require specific social science projects applied to personalized medicine. Hence, it includes a health and social sciences focus, including evaluation of “equality of access to innovative targeted therapies”. Indeed, new generation clinical trials are now based on complex multidimensional information and require specific equipment and staff to interpret genomic sequences. In contrary to classical cohort studies, these biology-driven trials challenge our traditional view of patient management in hospital structures and need to be studied from a sociologic point of view.